Skip to main content

[]

Intended for healthcare professionals
Skip to main content
Restricted access
Case report
First published online December 6, 2022

Fluocinolone acetonide implant (Iluvien®) for macular edema associated with retinitis pigmentosa: A case report

Abstract

Purpose

Macular edema can be observed in 20% of patients with retinitis pigmentosa (RP) and is often responsible of central vision impairment. Intraocular administration of corticosteroids (either triamcinolone or dexamethasone implant) has been found to be effective in that indication. We here describe the first report of a successful bilateral administration of fluocinolone acetonide implant in a patient with steroid-dependent macular edema associated to RP.

Methods

Case report.

Case report

A 34-year female patient with RP was referred for a one-year bilateral persistent ME. She had been refractory either to topical or to general carbonic anhydrase inhibitors. Bilateral off-label administration of 0.7 mg dexamethasone implant (Ozurdex®, Allergan, CA) was therefore decided. Efficacy and tolerance were very good in both eyes. Still, every four-month injections were required to maintain the macula dry. Off-label use of 0.19 mg fluocinolone acetonide (FAc) implant (Iluvien®, Alimera Sciences, GA) was then proposed and injected, first, in the right eye and, two-years after, in the left eye. No recurrences of the edema were observed from then on, i.e., for 3 years in the right eye and for 1 year in the left eye.

Conclusion

Intravitreal fluocinolone acetonide could represent a promising means in the therapeutic management of persistent steroid-dependent ME related to RP.

Get full access to this article

View all access and purchase options for this article.

References

1. Glybina IV, Kennedy A, Ashton P, et al. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci. août 2010; 51: 4243–4252.
2. Hajali M, Fishman GA, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol. août 2008; 92: 1065–1068.
3. Bakthavatchalam M, Lai FHP, Rong SS, et al. Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review. Surv Ophthalmol. juin 2018; 63: 329–339.
4. Alimera Sciences Limited, ILUVIEN 190 Micrograms Intravitreal Implant in Applicator, EMC, Hopkinton, MA, USA, 2019, https://www.medicines.org.uk/emc/medicine/27636#gref
5. Ribeiro F, Falcão MS. Off-Label use of 0.19 mg fluocinolone acetonide intravitreal implant: a systematic review. J Ophthalmol 2021; 2021: 6678364. https://doi.org/10.1155/2021/6678364
6. Glybina IV, Kennedy A, Ashton P, et al. Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Invest Ophthalmol Vis Sci. oct 2009; 50: 4847–4857. https://doi.org/10.1167/iovs.08-2831
7. Mansour AM, Sheheitli H, Kucukerdonmez C, et al. Intravitreal dexamethasone implant in retinitis Pigmentosa-related cystoid macular edema. Retina. févr 2018; 38: 416–423.

Cite article

Cite article

Cite article

OR

Download to reference manager

If you have citation software installed, you can download article citation data to the citation manager of your choice

Share options

Share

Share this article

Share with email
Email Article Link
Share on social media

Share access to this article

Sharing links are not relevant where the article is open access and not available if you do not have a subscription.

For more information view the Sage Journals article sharing page.

Information, rights and permissions

Information

Published In

Article first published online: December 6, 2022
Issue published: November 2023

Keywords

  1. Retinitis pigmentosa
  2. fluocinolone acetonide implant
  3. macular edema

Rights and permissions

© The Author(s) 2022.
Request permissions for this article.
PubMed: 36474351

Authors

Affiliations

Emilie Jomaa
Department of Ophtalmology, Bordeaux University Hospital, Bordeaux, France
Marie-Noëlle Delyfer
Department of Ophtalmology, Bordeaux University Hospital, Bordeaux, France
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, LEHA team, UMR 1219, F-33000 Bordeaux, France
Jean-François Korobelnik
Department of Ophtalmology, Bordeaux University Hospital, Bordeaux, France
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, LEHA team, UMR 1219, F-33000 Bordeaux, France

Notes

Emilie Jomaa, Vitreo-retinal Unit – Ophtalmology Department, Bordeaux University Hospital, Place Amélie Raba-Léon - 33000 Bordeaux, France. Email: [email protected]

Metrics and citations

Metrics

Journals metrics

This article was published in European Journal of Ophthalmology.

View All Journal Metrics

Article usage*

Total views and downloads: 120

*Article usage tracking started in December 2016


Articles citing this one

Receive email alerts when this article is cited

Web of Science: 0 view articles Opens in new tab

Crossref: 0

There are no citing articles to show.

Figures and tables

Figures & Media

Tables

View Options

Access options

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:

SCALA members can access this journal content using society membership credentials.

SCALA members can access this journal content using society membership credentials.


Alternatively, view purchase options below:

Purchase 24 hour online access to view and download content.

Access journal content via a DeepDyve subscription or find out more about this option.

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text